Production (Stage)
Minerva Neurosciences, Inc.
NERV
$1.84
$0.052.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 119.79% | 104.80% | 88.05% | -25.59% | -7.81% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 33.33% | 100.00% | 300.00% |
| Total Amortization of Deferred Charges | -58.20% | -33.20% | -8.20% | 20.19% | 71.81% |
| Total Other Non-Cash Items | -318.04% | -301.84% | -275.71% | -1.77% | -4.09% |
| Change in Net Operating Assets | -421.61% | -106.49% | -76.48% | 233.50% | 132.19% |
| Cash from Operations | 15.58% | -32.23% | -57.90% | -18.14% | -9.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 72.00% | -- |
| Cash from Financing | -- | -- | -100.00% | -100.44% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,411.06% | -505.71% | -404.84% | -1,123.93% | 93.88% |